Race Oncology Ltd (ASX:RAC, OTC:RAONF) has presented its Bisantrene Phase 2 AML trial data at the 65th American Society of Hematology Annual Conference in San Diego, USA, on December 9-12, 2023.
The oral poster presentation entitled 'Bisantrene in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) – An Openlabel, Phase II Study' describes clinical results from the first 20 patients treated on study since August 2021.
The presentation shows that Bisantrene, in combination with fludarabine and clofarabine, administered over four days induced a clinical response in six of 15, or 40%, of evaluable patients with advanced relapsed or refractory Acute Myeloid Leukaemia (R/R AML).
Five of these patients received a potentially curative stem cell transplant. The bisantrene combination was found to be safe and well-tolerated without clinically relevant cardiotoxicity or tumour lysis syndrome
The trial is running at the Sheba Medical Centre, Israel, under the supervision of key opinion leader Professor Arnon Nagler.
This presentation follows the release of the abstract to ASX on November 6, 2023.